Active Pharmaceutical Ingredients Market Latest Development Report 2021-2028 | Pfizer, Endo International plc, Dr. Reddy’s Laboratories Ltd., Novartis AG

Overview:
Active Pharmaceutical Ingredients (APIs) are used for prevention, treatment and diagnosis of disease. To attain the proper pharmacokinetics and pharmacodynamics parameters, the APIs cannot be used in the raw form as they are the unpolished form of drugs. Some specific medications like combination therapies include multiple active ingredients to treat various symptoms or to act in differently. There are different standards that are used to determine the APIs strength. However, these standards depend on brand to brand, according to the choice of company.

Request Sample Report + Related Graphs & Charts @:
https://www.coherentmarketinsights.com/insight/request-sample/738

Key Players in This Report Include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Endo International plc, Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Stada Arzneimittel AG, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Aurobindo Pharma Limited, Apotex Inc., Cipla Limited, Taro Pharmaceutical Industries Ltd., Biological E. Limited, CordenPharma International, Sun Pharmaceutical Industries Ltd., Glenmark Pharma, and Krka Pharmaceuticals.

Impact of COVID-19:

The COVID-19 pandemic has affected many industries across the globe. It has significantly disrupted supply of key materials due to forced lockdown and lack of raw materials and labors. This shortage of components and raw materials has also affected the supply chain of the global market of active pharmaceutical ingredients market. The COVID-19 pandemic has revealed the impact of China dominance on global supply of API and its raw material for global leaders and regulators.

Drivers:

Frequent investments in R&D is expected to boost growth of the global active pharmaceutical ingredients market. For instance, in October 2018, Lonza, a specialty CDMO partner to the biopharma industry, announced an expansion of its highly potent API (HPAPI) capacity for the specific support of antibody drug conjugate (ADC) payload manufacturing.

Rising prevalence of chronic diseases and expanding geographic presence of API manufacturers in the developing nations are also expected to augment growth of the global active pharmaceutical ingredients market. For instance, in September 2018, Olon announced acquisition of API production facility in Mahad, India for a long-term agreement with Sandoz.

Key Takeaways:

The global active pharmaceutical ingredients market is projected to have CAGR of 6.7% over the forecast period due to increasing prevalence of chronic diseases all over the world. For instance, cardiovascular diseases cause 17.7 million fatalities every year followed by cancer with 8.8 million, respiratory with 3.9 million and diabetes 1.6 million causing 80% of all premature NDC deaths.

High protein API segment is expected to witness a strong growth in the API market over the forecast period due to growing demand of high protein APIs for clinical stage drugs and approval of antibody drug conjugates (ADC). For instance, in May 2019, Kadcyla (ado-trastuzumab emtansine) product from Genentech USA, Inc. received approval of the U.S. FDA for treatment of HER2-positive early breast cancer (EBC) patients.

Request for customization in Report @ https://www.coherentmarketinsights.com/insight/request-customization/738

Regional analysis:

North America witnessed strong growth in the global global active pharmaceutical ingredients market in 2020, owing to rising demand for API in biopharmaceutical products and growing cases of chronic diseases in the region. For instance, in 2018, American Diabetes Association estimated diabetes affected about 34.2 million people, which is 10.5% of the overall population of U.S.

Major players:

Major players functioning in the global active pharmaceutical ingredients market include Pfizer, Inc., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lonza Group, Lupin Limited, Hikma Pharmaceuticals, Apotex Inc., Taro Pharmaceutical Industries Ltd., CordenPharma International, Sun Pharmaceutical Industries Ltd., Krka Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Endo International plc, Novartis AG, Amneal Pharmaceuticals LLC, Stada Arzneimittel AG, Fresenius Kabi, Aurobindo Pharma Limited, Cipla Limited, Biological E. Limited, , and Glenmark Pharma.

Get Discount On The Purchase Of This Report @: https://www.coherentmarketinsights.com/promo/buynow/738

1001 4th Ave, #3200 Seattle, WA 98154, United States.Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.